OriGene Technologies, the Rockville, MD-based life sciences company, has agreed to acquire Bothell, WA-based Blue Heron Biotechnology for an undisclosed amount. Blue Heron, founded in 1999, offers a service that synthesizes genes on demand for a wide variety of researchers and Big Pharma customers around the world. Blue Heron last made news in May, when the J. Craig Venter Institute said it used the company’s service as part of its effort to engineer the first bacterial cell that comes entirely from a synthetic genome.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
